Dual downregulation of microRNA 17-5p and E2F1 transcriptional factor in pediatric systemic lupus erythematosus patients

Abstract

The main objective of this study is to investigate the relative expression of miRNA 17-5p and one of its target genes E2F1 in the peripheral blood of systemic lupus erythematosus pediatric patients. The expression of miRNA 17-5p and its target E2F1 mRNA was analyzed by TaqMan real-time qPCR. Our results showed significant downregulation of miRNA 17-5p in SLE patients compared to healthy controls; moreover, miRNA 17-5p was more downregulated in patients on no treatment compared to those on treatment. Relative expression of E2F1, which is a target for miRNA 17-5p, was significantly downregulated as well on both mRNA and protein levels in SLE pediatric patients. In conclusion, our data show an unexpected dual downregulation of both miRNA 17-5p and its target gene E2F1 on the mRNA and protein levels. This may suggest an expression pattern of miRNA 17-5p and its target E2F1 that may be specific to SLE. [corrected].

Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases

“…Several inflammasome-regulating miRNAs are downregulated in SLE: miR-223-3p in naive B cells of SLE patients (112), miR-20a-5p in monocytes (113), and miR-17-5p in PBMCs of adult (114) and pediatric SLE patients (115). Moreover, miR-17-5p levels are diminished in untreated patients compared with those on treatment (116). Regarding lupus nephritis, Several transcripts coding for proteins that act as regulators of the NLRP3 inflammasome are targeted by miRNAs.…”

Paraquat and MPTP alter microRNA expression profiles, and downregulated expression of miR‐17‐5p contributes to PQ‐induced dopaminergic neurodegeneration

“…This signaling cascade is associated with a number of cell functions, including cell development, differentiation and apoptosis (Table ). However, a number of studies identified a role for miR‐17‐5p in several cancers (Chen et al, ; Hufbauer et al, ), immune response, Philadelphia chromosome‐negative myeloproliferative neoplasm (Hussein, Dralle, Theophile, Kreipe, & Bock, ), pediatric systemic lupus erythematosus (Aboelenein, Salah, Lashine, & Abdelaziz, ) and progression of lipid metabolism (Fontana et al, ; Klöting et al, ). However, a relationship between miR‐17‐5p and neurodegeneration is yet to be reported.…”

“…However, a relationship between miR‐17‐5p and neurodegeneration is yet to be reported. The transcription factor E2F1, a direct downstream target of c ‐myc, is negatively regulated by miR‐17‐5p, which may partially account for the antiapoptotic effects of these miRNAs (Aboelenein et al, ). Taken together, we speculate that the aberrant expression of miR‐17‐5p might partly be involved in PQ‐induced neurotoxicity, contributing to antiapoptotic effects and may play a critical role in the pathology of PD.…”

“…The results showed that PQ-induced miRNAs primarily participated in cell cycle changes, endocytosis, ubiquitin mediated proteolysis, MAPK signaling pathway, transforming growth factor-beta signaling pathway, and p53 signaling pathway (Tables 2). Among them, the cell cycle changes and endocytosis were the two most significant candidate pathways to be affected by PQ-induced downregulated miRNAs (Tables 2). The (Aboelenein, Salah, Lashine, & Abdelaziz, 2013) and progression of lipid metabolism (Fontana et al, 2008;Klöting et al, 2009). However, a relationship between miR-17-5p and neuro-…”